All articles tagged: Diffuse large B-cell lymphoma (C83.3)
HealthDay
20 June at 04.00 PM
ViPOR Results in Durable Remission in Specific Subtypes of LymphomaFor patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) yields durable remission, according to a study published in the June 20 issue of the New England Journal of Medicine.Christopher Melani, M.D., fro |
|
HealthDay
14 June at 03.35 PM
Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell TherapySecond tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England Journal of Medicine.Mark P. Hamilton, M.D., Ph.D., from Stanford University in California, and colleagues examined the occurrence of second tumors after CAR T-cell therapy since 2016. |
Evalytics
25 March at 05.57 AM
Some lymphomas become resistant to treatment. Gene discovery may offer path to overcome it.University of Wisconsin–Madison researchers have uncovered a critical process driving resistance in certain types of lymphoma, offering hope for patients who become resistant to standard treatments. The study focused on understanding why some patients with B-cell malignancies, such as mantle cell lymphoma and diffuse large B-cell lymphoma, develop resistance to Bruton tyrosine kinase inhibitors (B |
|
HealthDay
04 January at 03.44 PM
Liso-Cel Cost-Effective for Second-Line Relapsed/Refractory LymphomaLisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood Advances.Jee H. Choe, from the University of Southern California in Los Angeles, and colleagues evaluated the cost |
|
HealthDay
04 December at 11.21 PM
CAR-T Therapies Not Cost-Effective for Diffuse Large B-Cell LymphomaFor patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to a study published online Dec. 5 in the Annals of Internal Medicine.Amar H. Kelkar, M.D., M.P.H., from the Dana-Farbe |
Medical xPress
30 June at 07.40 AM
Decision to offer sedation for often-painful IUD insertion is 'groundbreaking,' health experts sayIntrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during the insertion. But it wasn't until recently that providers began to acknowledge this and do something about it. |
|
HealthDay
27 June at 03.19 PM
Immunoglobulin Replacement Therapy Beneficial for Blood CancersImmunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.Jacob D. Soum |
Medpage Today
26 June at 04.59 PM
When Was the Last Time You Really Talked With Your Patient?My 10 o'clock patient's name is Maria*. Her chart has three "health maintenance" flags that are bright red, indicating that she is more than 3 years overdue for a mammogram, more than 6 years overdue for a Pap smear, and has... |
|
Medpage Today
23 June at 09.21 PM
Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2DORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks... |
|
Medpage Today
22 June at 06.00 PM
Fenofibrate Slows Diabetic Retinopathy ProgressionORLANDO -- The cholesterol drug fenofibrate reduced progression of early eye disease among diabetes patients, the LENS trial showed. The fibrate reduced progression of early diabetic retinopathy or maculopathy by a relative... |
|
Medpage Today
22 June at 06.00 PM
Preventing Surgical-Site Infections; Drugs Go Head to Head for Ischemic StrokeTTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... |
|
|
Medical xPress
22 June at 05.20 PM
Lawsuit could challenge trust in Ozempic and other popular weight loss drugsThe manufacturers of the most popular weight loss drugs are being challenged in court. |
|
HealthDay
21 June at 03.38 PM
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is LowThe overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities, according to a study published online June 10 in JAMA Internal Medicine.Priti Bandi, Ph.D., from the American Cancer Society in Atlanta, and colleagues estimated the contemporary preval |
|
Medpage Today
13 June at 06.56 PM
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?Finding a way to dissociate the activity of effector T cells from regulatory T cells could make immune checkpoint inhibitors more effective in the 60% of melanoma patients who do not benefit or develop resistance to the drugs... |
|
Medpage Today
08 June at 04.00 PM
Here Are the Top Supreme Court Health Cases to WatchBy early July, the Supreme Court will release its most controversial rulings for the 2023-2024 term. The Court's 6-3 conservative supermajority has already overturned Roe v. Wade, sharply limited affirmative action, expanded... |
Newsletter for Healtcare
Join over 1.2M subscribers and receive one weekly email.
